^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PD-L1 inhibitor

    Related drugs:
    19h
    CA2660002: A Study of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ? 50% (2025-523586-18-00)
    P2/3, N=15, Not yet recruiting, Bristol-Myers Squibb Services Unlimited Company
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • pumitamig (BNT327)
    21h
    Randomised, multicentre phase II study of bevacizumab and paclitaxel induction followed by atezolizumab and nab-paclitaxel in patients with PD-L1-positive metastatic triple-negative breast cancer: protocol for the INDUCE trial (JBCRG-M10). (PubMed, BMJ Open)
    Study results will be presented at international conferences and published in a peer-reviewed journal. jRCTs041240039 NCT06793553.
    Clinical protocol • P2 data • Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • albumin-bound paclitaxel
    3d
    RTOG 1308: Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer (clinicaltrials.gov)
    P3, N=330, Completed, Radiation Therapy Oncology Group | Active, not recruiting --> Completed
    Trial completion
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • etoposide IV
    3d
    A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) (clinicaltrials.gov)
    P3, N=644, Active, not recruiting, AstraZeneca | Trial completion date: Nov 2028 --> Dec 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    PD-L1 expression • PD-L1 negative
    |
    carboplatin • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • Datroway (datopotamab deruxtecan-dlnk)
    3d
    A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA) (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, AstraZeneca | Trial completion date: Jun 2027 --> Mar 2027
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    EGFR wild-type • ALK wild-type
    |
    Imfinzi (durvalumab) • oleclumab (MEDI9447)
    3d
    GATEWAY: Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study (clinicaltrials.gov)
    P2, N=42, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    4d
    S2206: Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer (clinicaltrials.gov)
    P3, N=3680, Recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    MammaPrint®
    |
    Imfinzi (durvalumab) • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • daunorubicin
    4d
    A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=20, Suspended, Shanghai 6th People's Hospital | Recruiting --> Suspended | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial suspension • Trial primary completion date
    |
    Fruzaqla (fruquintinib) • Enweida (envafolimab)
    4d
    NAT-ESCC-01: Adebrelimab Plus Full-course Neoadjuvant Therapy for Resectable Locally Advanced ESCC (Phase 2) (clinicaltrials.gov)
    P2, N=200, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    carboplatin • albumin-bound paclitaxel • AiRuiLi (adebrelimab)
    4d
    KUNLUN: Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC (clinicaltrials.gov)
    P3, N=640, Active, not recruiting, AstraZeneca | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • Imfinzi (durvalumab) • 5-fluorouracil • capecitabine
    5d
    Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=30, Recruiting, West China Hospital | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker
    |
    Trodelvy (sacituzumab govitecan-hziy) • Cotelet (tagitanlimab)
    5d
    Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=43, Not yet recruiting, Jiangmen Central Hospital
    New P2 trial
    |
    cisplatin • carboplatin • etoposide IV • AiRuiLi (adebrelimab)